Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss management program.

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 2 includes Neo Performance Metals, Fannie Mae, ...

Current Target Price: $1040 Joseph Bonner, CFA -- Netflix has developed from upstart Hollywood outsider to being the central player in long-form streaming video, what has now become the future of the ...